SphynKx Therapeutics LLC is developing a portfolio of sphingosine kinase inhibitors that can up- or down-regulate blood levels of sphingosine 1-phosphate to treat fibrosis in different organs.

The company's lead program focuses on preventing fibrosis in chronic kidney disease by increasing circulating sphingosine 1-phosphate (S1P). A less advanced program seeks to treat idiopathic pulmonary fibrosis (IPF) by lowering S1P.